Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Novel Method Enables Isolation of Nearly Pure Population of Mammary Gland Stem Cells

By BiotechDaily International staff writers
Posted on 25 Apr 2013
Print article
The surface protein marker CD1d is highly expressed on mammary gland stem cells (MaSCs), and the presence of this protein was used in a novel method to isolate a remarkably pure MaSC population.

CD1d is a member of the CD1 (cluster of differentiation 1) family of glycoproteins expressed on the surface of various human antigen-presenting cells. They are nonclassical major histocompatibility complex (MHC) proteins, related to the class I MHC proteins, and are involved in the presentation of lipid antigens to T-cells.

The partial purification of mouse MaSCs using a combination of cell surface markers has improved understanding of their role in normal development and breast tumorigenesis. However, despite the significant improvement in techniques for MaSC enrichment, there is presently no methodology that adequately isolates pure MaSCs.

To correct this lack, investigators at Cold Spring Harbor Laboratory (NY, USA) utilized the fact that MaSCs replicate very slowly to develop a method for their purification based on incorporation of a green fluorescent protein into the nuclei of various mammary cells including MaSCs. Since MaSCs replicate less often than other cell types, they retain more of the green fluorescent protein and can be isolated by cell sorting techniques that recognize CD1d.

The investigators reported in the April 11, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that working with a remarkably pure MaSC population, they were able to functionally characterize a set of MaSC-enriched genes and discovered factors controlling MaSC survival.

"With this advancement, we are now able to profile normal and cancer stem cells at a very high degree of purity, and perhaps point out which genes should be investigated as the next breast cancer drug targets," said senior author Dr. Gregory Hannon, professor of molecular biology at Cold Spring Harbor Laboratory.

Related Links:

Cold Spring Harbor Laboratory



Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

Bio-Innovation Agreement to Strengthen Ties between Canada and Israel

A recently signed agreement aims at encouraging academic and entrepreneurial ties in the field of bio-innovation between a Canadian and an Israeli university. The agreement will establish a strong relationship between the University of Toronto (Canada) – in the form of the Institute of Biomaterials and Biomedical Engineering... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.